| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.2 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | 0.056 | 0.3 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.059 | 0.3 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.3 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.3 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |